Neurobiology of Aging
Volume 30, Issue 4 , Pages 534-545 , April 2009

Total cholesterol and oxysterols: Early markers for cognitive decline in elderly?

  • T.N. van den Kommer

      Affiliations

    • Longitudinal Aging Study Amsterdam, EMGO Institute, VU University Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 204449337; fax: +31 204446775.
    • ,
  • M.G. Dik

      Affiliations

    • Longitudinal Aging Study Amsterdam, EMGO Institute, VU University Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
    • Department of Nursing Home Medicine, EMGO Institute, VU University Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
    • ,
  • H.C. Comijs

      Affiliations

    • Longitudinal Aging Study Amsterdam, EMGO Institute, VU University Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
    • Department of Psychiatry, VU University Medical Center & GGZ Buitenamstel, AJ Ernststraat 887, 1081 HL Amsterdam, The Netherlands
    • ,
  • K. Fassbender

      Affiliations

    • Department of Neurology, University Clinic of the Saarland, Kirrberger Str., D-68421 Homburg, Germany
    • ,
  • D. Lütjohann

      Affiliations

    • Department of Clinical Pharmacology, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany
    • ,
  • C. Jonker

      Affiliations

    • Longitudinal Aging Study Amsterdam, EMGO Institute, VU University Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands

Received 7 February 2007 ,Revised 13 July 2007 ,Accepted 9 August 2007.

References 

  1. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell Biol. 2004;167(5):953–960
  2. Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 2004;24(5):806–815
  3. Björkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U. Oxysterols and Alzheimer's disease. Acta Neurol. Scand. 2006;114:43–49
  4. Bremmer MA, Hoogendijk WJG, Deeg DJH, Schoevers RA, Schalk BWM, Beekman ATF. Depression in older age is a risk factor for first ischemic cardiac events. Am. J. Geriatr. Psychiatry. 2006;14(6):523–530
  5. Deeg DJH, Westendorp-de Serière M. Autonomy and Well-Being in the Aging Population I: Report from the Longitudinal Aging Study Amsterdam 1992–1993. Amsterdam, The Netherlands: VU University Press; 1994;
  6. Dik MG, Deeg DJH, Bouter LM, Corder EH, Kok A, Jonker C. Stroke and apolipoprotein E ɛ4 are independent risk factors for cognitive decline: a population-based study. Stroke. 2000;31(10):2431–2436
  7. Dik MG, Jonker C, Bouter LM, Geerlings MI, Van Kamp GJ, Deeg DJH. APOE-ɛ4 is associated with memory decline in cognitively impaired elderly. Neurology. 2000;54(7):1492–1497
  8. Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology. 2000;54(1):240–242
  9. Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR. Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology. 2004;62(10):1869–1871
  10. Folstein MF, Folstein SE, Mchugh PR. Mini-mental state. A practical method for grading cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12(3):189–198
  11. Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, et al. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology. 2006;66(2):223–227
  12. Havekes LM, De Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J. Lipid Res. 1987;28(4):455–463
  13. Heverin M, Bogdanovic N, Lütjohann D, Bayer T, Pikuleva I, Bretillon L, et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 2004;45(1):186–193
  14. Heverin M, Meaney S, Lütjohann D, Diczfalusy U, Wahren J, Björkhem I. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J. Lipid Res. 2005;46(5):1047–1052
  15. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology. 1995;45(6):1092–1096
  16. Jolles J, Verhey FRJ, Riedel WJ, Houx PJ. Cognitive impairment in elderly people: predisposing factors and implications for experimental drug studies. Drugs Aging. 1995;7(6):459–479
  17. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann. Neurol. 1997;42(5):776–782
  18. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447–1451
  19. Kölsch H, Heun R, Kerksiek A, Von Bergmann K, Maier W, Lütjohann D. Altered levels of plasma 24S-and 27-hydroxycholesterol in demented patients. Neurosci. Lett. 2004;368(3):303–308
  20. Kriegsman DMW, Penninx BWJH, Van Eijk J, Boeke AJP, Deeg DJH. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients’ self-reports and on determinations of inaccuracy. J. Clin. Epidemiol. 1996;49:1407–1417
  21. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ. 1997;315(7115):1045–1049
  22. Laurin D, Verreault R, Lindsay J, Dewailly E, Holub BJ. Omega-3 fatty acids and risk of cognitive impairment and dementia. J. Alzheimer's Dis. 2003;5(4):315–322
  23. Lehtimäki T, Ojala P, Rontu R, Goebeler S, Karhunen PJ, Jylhä M, et al. Interleukin-6 modulates plasma cholesterol and C-reactive protein concentrations in nonagenarians. J. Am. Geriatr. Soc. 2005;53(9):1552–1558
  24. Leoni V, Masterman T, Patel P, Meaney S, Diczfalusy U, Björkhem I. Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood–brain and blood–cerebrospinal fluid barriers. J. Lipid Res. 2003;44(4):793–799
  25. Lütjohann D, Breuer O, Ahlborg G, Nennesmio I, Siden A, Diczfalusy U, et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl. Acad. Sci. U.S.A. 1996;93(18):9799–9804
  26. Lütjohann D, Papassotiropoulos A, Björkhem I, Locatelli S, Bagli M, Oehring RD, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid Res. 2000;41(2):195–198
  27. Lütjohann D, Stroick M, Bertsch T, Kuhl S, Lindenthal B, Thelen K, et al. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids. 2004;69:431–438
  28. Michikawa M. Role of cholesterol in amyloid cascade: cholesterol-dependent modulation of tau phosphorylation and mitochondrial function. Acta Neurol. Scand. 2006;114:21–26
  29. Mielke MM, Zandi PP, Sjögren M, Gustafson D, Ostling S, Steen B, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology. 2005;64(10):1689–1695
  30. Moller JT, Cluitmans P, Rasmussen LS, Houx P, Rasmussen H, Canet J, et al. Long-term postoperative cognitive dysfunction in the elderly: ISPOCD1 study. Lancet. 1998;351(9106):857–861
  31. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17(1):14–20
  32. Panza F, D’Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, et al. Lipid metabolism in cognitive decline and dementia. Brain Res. Rev. 2006;51(2):275–292
  33. Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport. 2000;11(9):1959–1962
  34. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Garcia MF, Manjon M, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61(2):199–205
  35. Piccinin AM, Rabbitt PM. Contribution of cognitive abilities to performance and improvement on a substitution coding task. Psychol. Aging. 1999;14(4):539–551
  36. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta. 1987;917(1):148–161
  37. Poirier J. Apolipoprotein E in the brain and its role in Alzheimer's disease. J. Psychiatry Neurosci. 1996;21(2):128–134
  38. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl. Psychol. Meas. 1977;1:385–401
  39. Reinhard O, Rood-Bakker D. Alcoholgebruik in beeld. Standaardmeetlat. Rotterdam: Nederlands Economisch Instituut; 1998;(in Dutch)
  40. Rey A. L’examen clinique en psychologie. Paris, France: Presses Universitaire de France; 1964;
  41. Romas SN, Tang MX, Berglund L, Mayeux R. APOE genotype, plasma lipids lipoproteins, and AD in community elderly. Neurology. 1999;53(3):517–521
  42. Salthouse TA. The processing-speed theory of adult age differences in cognition. Psychol. Rev. 1996;103(3):403–428
  43. Schalk BWM, Visser M, Deeg DJH, Bouter LM. Lower levels of serum albumin and total cholesterol and future decline in functional performance in older persons: the Longitudinal Aging Study Amsterdam. Age Ageing. 2004;33(3):266–272
  44. Solfrizzi V, Panza F, D’Introno A, Colacicco Am, Capurso C, Basile AM, et al. Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 2002;72(6):732–736
  45. Solfrizzi V, D’Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, et al. Circulating biomarkers of cognitive decline and dementia. Clin. Chim. Acta. 2006;364(1/2):91–112
  46. Solomon A, Kåreholt I, Ngandu T, Winblad B, Nissinen A, Tuomihelto J, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology. 2007;68(10):751–756
  47. Tan ZS, Seshadri S, Beiser A, Wilson PWF, Kiel DP, Tocco M, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease—The Framingham study. Arch. Intern. Med. 2003;163(9):1053–1057
  48. Teunissen CE, De Vente J, Von Bergmann K, Bosma H, Van Boxtel MP, De Bruijn C, et al. Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. Neurobiol. Aging. 2003;24(1):147–155
  49. Twisk JW, De Vente W. Roaming through methodology. XXII. Application of techniques for longitudinal data analysis. Ned. Tijdschr. Geneeskd. 2000;144(35):1680–1683(in Dutch)
  50. van den Heuvel N, Smits CHM, Deeg DJH, Beekman ATF. Personality: a moderator of the relation between cognitive functioning and depression in adults aged 55-85?. J. Affect. Disord. 1996;41:229–240
  51. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am. J. Clin. Nutr. 2007;85(4):1142–1147
  52. Wirths O, Thelen K, Breyhan H, Lúzon-Toro B, Hoffmann KH, Falkai P, et al. Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. Exp Gerontol. 2006;41(2):220–224

PII: S0197-4580(07)00337-5

doi: 10.1016/j.neurobiolaging.2007.08.005

Neurobiology of Aging
Volume 30, Issue 4 , Pages 534-545 , April 2009

Article Tools

* Image Usage & Resolution